Claims for Patent: 6,589,941

Summary for Patent: 6,589,941

Title:	Utilization of 5\' substituted nucleosides for resistance formation in cytoclastic treatment, and drug containing these nucleosides, polymers, methods of use and compositions
Abstract:	The invention relates to a method of producing a composition and to a composition for preventing or reducing formation of resistance in cytostatic treatment comprising combining BVDU, a salt thereof or BVDU in protected form or in prodrug form with at least one cytostatic agent in order to prevent or reduce the formation of resistance during cytostatic treatment. The present invention is also directed to a method of reducing resistance in cytostatic treatment comprising delivering therapeutically-effective amount of at least one cytostatic agent and a therapeutically effective amount of BVDU, a salt thereof, or BVDU in protected form or in prodrug form.
Inventor(s):	Fahrig; Rudolf (Hannover, DE), Steinkamp-Zucht; Angela (Hannover, DE)
Assignee:	Resprotect GmbH (Dresden, DE)
Application Number:	09/520,901
Patent Claims:	1. A composition for preventing or reducing the formation of resistance in cytostatic treatment comprising: (E)-5-(2-bromovinyl-)2'-deoxyuridine (BVDU), or a salt thereof, or BVDU in protected form or prodrug form, and at least one cytostatic agent, which is an anti-carcinogenic agent and which is not 5-fluorouracil, wherein the quantity of BVDU is effective to produce a concentration of 0.02 .mu.g/ml to 10 .mu.g/ml in blood, and the at least one cytostatic agent comprises alkylating agents selected from one or more of bisulfan, carboplatin, cisplatin, melphalan, cyclophosphamide, ifosfamide, chloroambucil, mechlorethamine HCl, carmustine, lomustine, polifeprosan 20 or streptozocin sterile powder. 2. The composition of claim 1, wherein the quantity of BVDU, or a salt thereof, or BVDU in protected form or prodrug form is effective to produce a concentration of BVDU of 0.05 .mu.g/ml to 5 .mu.g/ml in blood. 3. A composition for preventing or reducing the formation of resistance in cytostatic treatment comprising: (E)-5-(2-bromovinyl-)2'-deoxyuridine (BVDU), or a salt thereof, or BVDU in protected form or prodrug form, and at least one cytostatic agent, which is an anti-carcinogenic agent and which is not 5-fluorouracil, wherein the quantity of BVDU is effective to produce a concentration of 0.02 .mu.g/ml to 10 .mu.g/ml in blood, and the at least one cytostatic agent comprises antibotics selected from one or more of doxorubicin hydrochloride, bleomycin sulfate, daunorubicin HCl, diactinomycin, daunorubicin citrate, idarubicin HCl, plicamycin, mitomycin, pentostatin, mitoxantrone, or valrubicin. 4. A composition for preventing or reducing the formation of resistance in cytostatic treatment comprising: (E)-5-(2-bromovinyl-)2'-deoxyuridine (BVDU), or a salt thereof, or BVDU in protected form or prodrug form, and at least one cytostatic agent, which is an anti-carcinogenic agent and which is not 5-fluorouracil, wherein the quantity of BVDU is effective to produce a concentration of 0.02 .mu.g/ml to 10 .mu.g/ml in blood, and the at least one cytostatic agent comprises hormonal agonists/antagonists selected from one or more of androgens, antiandrogens, antiestrogens, estrogen and nitrogen combinations, estrogens, gonadotropin releasing hormone (GNRH) analogues, progestins or immunomudulators. 5. The composition of claim 4, wherein the hormonal agonists/antagonists are androgens and the androgens are selected from one or more of methyltestosterone, nilutamide, or testolactone. 6. The composition of claim 4, wherein the hormonal agonists/antagonists are antiandrogens and the antiandrogens are selected from one or more of bicalutamide or flutamide. 7. The composition of claim 4, wherein the hormonal agonists/antagonists are antiestrogens and the antiestrogens are selected from one or more of anastrozole, toremifene citrate, or tamoxifen citrate. 8. The composition of claim 4, wherein the hormonal agonists/antagonists are estrogen and nitrogen combinations and the estrogen and nitrogen combinations is estramustine phosphate sodium. 9. The composition of claim 4, wherein the hormonal agonists/antagonists are estrogens and the estrogens are selected from one or more of ethinyl estradiol, esterified estrogen, or conjugated estrogen. 10. The composition of claim 4, wherein the hormonal agonists/antagonists are GNRH analogues and the GNRH analogues are selected from one or more of leuprolide acetate or goserelin acetate. 11. The composition of claim 4, wherein the hormonal agonists/antagonists are progestins and the progestins are selected from one or more of medroxyprogesterone acetate or magestrol acetate. 12. The composition of claim 4, wherein the hormonal agonists/antagonists are immunomodulators and the immunomodulators are selected from one or more of levamisole hydrochloride or aldesleukin. 13. A composition for preventing or reducing the formation of resistance in cytostatic treatment comprising: (E)-5-(2-bromovinyl-)2'-deoxyuridine (BVDU), or a salt thereof, or BVDU in protected form or prodrug form, and at least one cytostatic agent, which is an anti-carcinogenic agent and which is not 5-fluorouracil, wherein the quantity of BVDU is effective to produce a concentration of 0.02 .mu.g/ml to 10 .mu.g/ml in blood, and the at least one cytostatic agent is selected from one or more of allopurinol sodium, dolasetron mesylate, pamidronate disodium, etidronate disodium, fluconazole, erythropoietin, levamisole hydrochloride, amifostine, granisetron hydrochloride, leucovorin, sargramostim, dronabinol, 2-mercaptoethane sulfonate, filgrastim, octreotide acetate, pilocarpine hydrochloride, dexrazoxane, ondansetron hydrochloride, irinotecan hydrochloride, dacarbazine, asparaginase, etoposide phosphate, gemcitabine HCl, trastuzumab, altretamine, topotecan hydrochloride, hydroxyurea, mitotane, interferon alfa-2b, procarbazine hydrochloride, vinorelbine tartrate, pegaspargase, vincaleukoblastine, 22-oxo, sulfate (1:1)(salt), denileukin diftitox, rituximab, aldesleukin, interferon alfa-2a, docetaxel, paclitaxel, BCG Live (Intravesical), BCG Live, vinblastine sulfate, etoposide, teniposide, or tretinoin. 14. A composition for preventing or reducing the formation of resistance in cytostatic treatment comprising: (E)-5-(2-bromovinyl-)2'-deoxyuridine (BVDU), or a salt thereof, or BVDU in protected form or prodrug form, and at least one cytostatic agent, which is an anti-carcinogenic agent and which is not 5-fluorouracil, wherein the quantity of BVDU is effective to produce a concentration of 0.02 .mu.g/ml to 10 .mu.g/ml in blood, and the at least one cytostatic agent comprises steroids and combinations selected from one or more of cortisone acetate, dexamethasonel, dexamethasone acetate, betamethasone sodium phosphate and betamethasone sodium phosphate and betamethasone, hydrocortisone, hydrocortisone sodium phosphate, prednisolone sodium phosphate, prednisolone or methylprednisolone sodium succinate. 15. A method of reducing resistance in cytostatic treatment comprising delivering to a host therapeutically-effective amount of at least one cytostatic agent, which is an anti-carcinogenic agent and which is not 5-fluorouracil, and therapeutically-effective amount of BVDU, a salt thereof, or BVDU in protected form or prodrug form. 16. The method of claim 15, wherein the therapeutically-effective amount of BVDU is an amount effective to produce a blood concentration of from about 0.02 .mu.g/ml to about 10 .mu.g/ml. 17. The method of claim 16, wherein the therapeutically-effective amount of BVDU is an amount effective to produce a blood concentration of from about 0.05 .mu.g/ml to about 5 .mu.g/ml. 18. The method of claim 15, wherein the at least one cytostatic agent is selected from alkaloids, alkylating agents, antibiotics, anti-metabolites, hormonal agonists/antagonists or steroids and combinations. 19. A composition for preventing or reducing the formation of resistance in cytostatic treatment comprising: (E)-5-(2-bromovinyl-)2'-debxyuridine (BVDU), or a salt thereof, or BVDU in protected form or prodrug form, and at least one cytostatic agent, which is an anti-carcinogenic agent and which is not 5-fluorouracil, wherein the quantity of BVDU is effective to produce a concentration of 0.02 .mu.g/ml to 10 .mu.g/ml in blood, and the at least one cytostatic agent is adriamycin. 20. The method of claim 18, wherein the at least one cytostatic agent is adriamycin. 21. The method of reducing resistance in cytostatic treatment of claim 18, wherein the at least one cytostatic agent are alkylating agents and the alkylating agents are selected from one or more of bisulfan, carboplatin, cisplatin, melphalan, cyclophosphamide, ifosfamide, chloroambucil, mechlorethamine HCl, carmustine, lomustine, polifeprosan 20 or streptozocin sterile powder. 22. The method of reducing resistance in cytostatic treatment of claim 18, wherein the at least one cytostatic agent are antibiotics and the antibiotics are selected from one or more of doxorubicin hydrochloride, bleomycin sulfate, daunorubicin HCl, diactinomycin, daunorubicin citrate, idarubicin HCl, plicamycin, mitomycin, pentostatin, mitoxantrone, or valrubicin. 23. The method of reducing resistance in cytostatic treatment of claim 18, wherein the at least one cytostatic agent are anti-metabolites and the anti-metabolites are selected from one or more of cytarabine, fludarabine phosphate, floxuridine, cladribine, mercaptopurine, thioguanine, or capecitabine. 24. The method of reducing resistance in cytostatic treatment of claim 18, wherein the at least one cytostatic agent are hormonal agonists/antagonists and the hormonal agonists/antagonists are selected from androgens, antiandrogens, antiestrogens, estrogen and nitrogen combinations, estrogens, gonadotropin releasing hormone (GNRH) analogues, progestins or immunomudulators. 25. The method of reducing resistance in cytostatic treatment of claim 24, wherein the hormonal agonists/antagonists are androgens and the androgens are selected from one or more of methyltestosterone, nilutamide, or testolactone. 26. The method of reducing resistance in cytostatic treatment of claim 24, wherein the hormonal agonists/antagonists are antiandrogens and the antiandrogens are selected from one or more of bicalutamide or flutamide. 27. The method of reducing resistance in cytostatic treatment of claim 24, wherein the hormonal agonists/antagonists are antiestrogens and the antiestrogens are selected from one or more of anastrozole, toremifene citrate, or tamoxifen citrate. 28. The method of reducing resistance in cytostatic treatment of claim 24, wherein the hormonal agonists/antagonists are estrogen and nitrogen combinations and the estrogen and nitrogen combinations is estramustine phosphate sodium. 29. The method of reducing resistance in cytostatic treatment of claim 24, wherein the hormonal agonists/antagonists are estrogens and the estrogens are selected from one or more of ethinyl estradiol, esterified estrogen, or conjugated estrogen. 30. The method of reducing resistance in cytostatic treatment of claim 24, wherein the hormonal agonists/antagonists are GNRH analogues and the GNRH analogues are selected from one or more of leuprolide acetate or goserelin acetate. 31. The method of reducing resistance in cytostatic treatment of claim 24, wherein the hormonal agonists/antagonists are progestins and the progestins are selected from one or more of medroxyprogesterone acetate or magestrol acetate. 32. The method of reducing resistance in cytostatic treatment of claim 24, wherein the hormonal agonists/antagonists are immunomodulators and the immunomodulators are selected from one or more of levamisole hydrochloride or aldesleukin. 33. The method of reducing resistance in cytostatic treatment of claim 18, wherein the at least one cytostatic agent is selected from one or more of allopurinol sodium, dolasetron mesylate, pamidronate disodium, etidronate disodium, fluconazole, erythropoietin, levamisole hydrochloride, amifostine, granisetron hydrochloride, leucovorin, sargramostim, dronabinol, 2-mercaptoethane sulfonate, filgrastim, octreotide acetate, pilocarpine hydrochloride, dexrazoxane, ondansetron hydrochloride, irinotecan hydrochloride, dacarbazine, asparaginase, etoposide phosphate, gemcitabine HCl, trastuzumab, altretamine, topotecan hydrochloride, hydroxyurea, mitotane, interferon alfa-2b, procarbazine hydrochloride, vinorelbine tartrate, pegaspargase, vincaleukoblastine, 22-oxo, sulfate (1:1)(salt), denileukin diftitox, rituximab, aldesleukin, interferon alfa-2a, docetaxel, paclitaxel, BCG Live (Intravesical), BCG Live, vinblastine sulfate, etoposide, teniposide, or tretinoin. 34. The method of reducing resistance in cytostatic treatment of claim 18, wherein the at least one cytostatic agent are steroids and combinations and the steroids and combinations are selected from one or more of cortisone acetate, dexamethasonel, dexamethasone acetate, betamethasone sodium phosphate and betamethasone, hydrocortisone, hydrocortisone sodium phosphate, prednisolone sodium phosphate, prednisolone or methylprednisolone sodium succinate. 35. A method of reducing resistance in cytostatic treatment comprising delivering to a host therapeutically-effective amount of at least one cytostatic agent, which is not 5-fluorouracil, and therapeutically-effective amount of BVDU, a salt thereof, or BVDU in protected form or prodrug form, wherein the at least one cytostatic agent is selected from one or more of alkaloids, alkylating agents, antibiotics, anti-metabolites, hormonal agonists/antagonists or steroids and combinations. 36. The method of reducing resistance in cytostatic treatment of claim 35, wherein the at least one cytostatic agent is selected from one or more of alkaloids, alkylating agents, antibiotics, anti-metabolites, hormonal agonists/antagonists or steroids and combinations. 37. The method of reducing resistance in cytostatic treatment of claim 36, wherein the at least one cytostatic agent are alkylating agents and the alkylating agents are selected from one or more of bisulfan, carboplatin, cisplatin, melphalan, cyclophosphamide, ifosfamide, chloroambucil, mechlorethamine HCl, carmustine, lomustine, polifeprosan 20 or streptozocin sterile powder. 38. The method of reducing resistance in cytostatic treatment of claim 36, wherein the at least one cytostatic agent are antibiotics and the antibiotics are selected from one or more of doxorubicin hydrochloride, bleomycin sulfate, daunorubicin HCl, diactinomycin, daunorubicin citrate, idarubicin HCl, plicamycin, mitomycin, pentostatin, mitoxantrone, or valrubicin. 39. The method of reducing resistance in cytostatic treatment of claim 36, wherein the at least one cytostatic agent are anti-metabolites and the anti-metabolites are selected from one or more of cytarabine, fludarabine phosphate, floxuridine, cladribine, mercaptopurine, thioguanine, or capecitabine. 40. The method of reducing resistance in cytostatic treatment of claim 36, wherein the at least one cytostatic agent are hormonal agonists/antagonists and the hormonal agonists/antagonists are selected from androgens, antiandrogens, antiestrogens, estrogen and nitrogen combinations, estrogens, gonadotropin releasing hormone (GNRH) analogues, progestins or immunomudulators. 41. The method of reducing resistance in cytostatic treatment of claim 40, wherein the hormonal agonists/antagonists are androgens and the androgens are selected from one or more of methyltestosterone, nilutamide, or testolactone. 42. The method of reducing resistance in cytostatic treatment of claim 40, wherein the hormonal agonists/antagonists are antiandrogens and the antiandrogens are selected from one or more of bicalutamide or flutamide. 43. The method of reducing resistance in cytostatic treatment of claim 40, wherein the hormonal agonists/antagonists are antiestrogens and the antiestrogens are selected from one or more of anastrozole, toremifene citrate, or tamoxifen citrate. 44. The method of reducing resistance in cytostatic treatment of claim 40, wherein the hormonal agonists/antagonists are estrogen and nitrogen combinations and the estrogen and nitrogen combinations is estramustine phosphate sodium. 45. The method of reducing resistance in cytostatic treatment of claim 40, wherein the hormonal agonists/antagonists are estrogens and the estrogens are selected from one or more of ethinyl estradiol, esterified estrogen, or conjugated estrogen. 46. The method of reducing resistance in cytostatic treatment of claim 40, wherein the hormonal agonists/antagonists are GNRH analogues and the GNRH analogues are selected from one or more of leuprolide acetate or goserelin acetate. 47. The method of reducing resistance in cytostatic treatment of claim 40, wherein the hormonal agonists/antagonists are progestins and the progestins are selected from one or more of medroxyprogesterone acetate or magestrol acetate. 48. The method of reducing resistance in cytostatic treatment of claim 40, wherein the hormonal agonists/antagonists are immunomodulators and the immunomodulators are selected from one or more of levamisole hydrochloride or aldesleukin. 49. The method of reducing resistance in cytostatic treatment of claim 36, wherein the at least one cytostatic agent is selected from one or more of allopurinol sodium, dolasetron mesylate, pamidronate disodium, etidronate disodium, fluconazole, erythropoietin, levamisole hydrochloride, amifostine, granisetron hydrochloride, leucovorin, sargramostim, dronabinol, 2-mercaptoethane sulfonate, filgrastim, octreotide acetate, pilocarpine hydrochloride, dexrazoxane, ondansetron hydrochloride, irinotecan hydrochloride, dacarbazine, asparaginase, etoposide phosphate, gemcitabine HCl, trastuzumab, altretamine, topotecan hydrochloride, hydroxyurea, mitotane, interferon alfa-2b, procarbazine hydrochloride, vinorelbine tartrate, pegaspargase, vincaleukoblastine, 22-oxo, sulfate (1:1)(salt), denileukin diftitox, rituximab, aldesleukin, interferon alfa-2a, docetaxel, paclitaxel, BCG Live (Intravesical), BCG Live, vinblastine sulfate, etoposide, teniposide, or tretinoin. 50. The method of reducing resistance in cytostatic treatment of claim 36, wherein the at least one cytostatic agent are steroids and combinations and the steroids and combinations are selected from one or more of cortisone acetate, dexamethasonel, dexamethasone acetate, betamethasone sodium phosphate and betamethasone, hydrocortisone, hydrocortisone sodium phosphate, prednisolone sodium phosphate, prednisolone or methylprednisolone sodium succinate. 51. The method of reducing resistance in cytostatic treatment of claim 35, wherein the therapeutically-effective amount of BVDU is an amount effective to produce a blood concentration of from about 0.02 .mu.g/ml to about 10 .mu.g/ml. 52. The method of reducing resistance in cytostatic treatment of claim 51, wherein the therapeutically-effective amount of BVDU is an amount effective to produce a blood concentration of from about 0.05 .mu.g/ml to about 5 .mu.g/ml. 53. The method of reducing resistance in cytostatic treatment of claim 35, wherein the at least one cytostatic agent is adriamycin.

Details for Patent 6,589,941

Applicant	Tradename	Biologic Ingredient	Dosage Form	BLA	Approval Date	Patent No.	Expiredate
Recordati Rare Diseases, Inc.	ELSPAR	asparaginase	For Injection	101063	01/10/1978		2015-02-01
Merck Teknika Llc	TICE BCG	bcg live	For Injection	102821	06/21/1989		2015-02-01
Merck Sharp & Dohme Corp.	INTRON A	interferon alfa-2b	For Injection	103132	06/04/1986		2015-02-01
Merck Sharp & Dohme Corp.	INTRON A	interferon alfa-2b	For Injection	103132			2015-02-01